arXiv.itsnick.co

an independent field guide to 23 million papers from arXiv & OpenAlex — not affiliated with arXiv.org

Author

Keith R. Abrams

46 papers · 1994–2026

1994: 11995: 01996: 01997: 01998: 11999: 02000: 12001: 02002: 02003: 02004: 02005: 02006: 12007: 02008: 02009: 02010: 02011: 32012: 12013: 32014: 12015: 42016: 32017: 22018: 62019: 52020: 52021: 12022: 12023: 12024: 02025: 32026: 3
1994peak 6 in 20182026

Frequent co-authors

Papers

showing 1–25 of 46 RSS

Hierarchical models in generalized synthesis of evidence: an example based on studies of breast cancer screening

Teresa C. Prevost, Keith R. Abrams, David R. Jones

Statistics and Probability · Statistics in Medicine · · cited 138× · DOI ↗ · more like this ·

Evidence regarding the potential benefits of a particular health care intervention is often available from a variety of disparate sources. However, formal synthesis of such evidence has traditionally concentrated almost exclusively on that derived from randomized studies, although for a range of conditions the randomized evidence will be less than adequate due to economic, organizational or ethical considerations. In such situations a formal synthesis of the evidence that is available from observational studies can be valuable whilst awaiting higher quality evidence from randomized trials. Consideration of randomized studies alone may be appropriate when assessing the efficacy of an intervention, but assessment of the effectiveness of such an intervention within a more general target population may be improved by consideration of evidence from non-randomized studies as well. Standard…

Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study

James P. Morden, Paul C. Lambert, Nicholas Latimer +2 more

Statistics and Probability · BMC Medical Research Methodology · · cited 117× · DOI ↗ · more like this ·

BACKGROUND: We investigate methods used to analyse the results of clinical trials with survival outcomes in which some patients switch from their allocated treatment to another trial treatment. These included simple methods which are commonly used in medical literature and may be subject to selection bias if patients switching are not typical of the population as a whole. Methods which attempt to adjust the estimated treatment effect, either through adjustment to the hazard ratio or via accelerated failure time models, were also considered. A simulation study was conducted to assess the performance of each method in a number of different scenarios. RESULTS: 16 different scenarios were identified which differed by the proportion of patients switching, underlying prognosis of switchers and the size of true treatment effect. 1000 datasets were simulated for each of these and all methods…

Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method

Nicholas Latimer, Keith R. Abrams, Paul C. Lambert +5 more

Statistics and Probability · Statistical Methods in Medical Research · · cited 101× · DOI ↗ · more like this ·

Estimates of the overall survival benefit of new cancer treatments are often confounded by treatment switching in randomised controlled trials (RCTs) - whereby patients randomised to the control group are permitted to switch onto the experimental treatment upon disease progression. In health technology assessment, estimates of the unconfounded overall survival benefit associated with the new treatment are needed. Several switching adjustment methods have been advocated in the literature, some of which have been used in health technology assessment. However, it is unclear which methods are likely to produce least bias in realistic RCT-based scenarios. We simulated RCTs in which switching, associated with patient prognosis, was permitted. Treatment effect size and time dependency, switching proportions and disease severity were varied across scenarios. We assessed the performance of…

Flexible parametric joint modelling of longitudinal and survival data

Michael J. Crowther, Keith R. Abrams, Paul C. Lambert

Statistics and Probability · Statistics in Medicine · · cited 68× · DOI ↗ · more like this ·

The joint modelling of longitudinal and survival data is a highly active area of biostatistical research. The submodel for the longitudinal biomarker usually takes the form of a linear mixed effects model. We describe a flexible parametric approach for the survival submodel that models the log baseline cumulative hazard using restricted cubic splines. This approach overcomes limitations of standard parametric choices for the survival submodel, which can lack the flexibility to effectively capture the shape of the underlying hazard function. Numerical integration techniques, such as Gauss-Hermite quadrature, are usually required to evaluate both the cumulative hazard and the overall joint likelihood; however, by using a flexible parametric model, the cumulative hazard has an analytically tractable form, providing considerable computational benefits. We conduct an extensive simulation…

Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study

Nicholas Latimer, Keith R. Abrams, Paul C. Lambert +2 more

Statistics and Probability · Statistical Methods in Medical Research · · cited 55× · DOI ↗ · more like this ·

When patients randomised to the control group of a randomised controlled trial are allowed to switch onto the experimental treatment, intention-to-treat analyses of the treatment effect are confounded because the separation of randomised groups is lost. Previous research has investigated statistical methods that aim to estimate the treatment effect that would have been observed had this treatment switching not occurred and has demonstrated their performance in a limited set of scenarios. Here, we investigate these methods in a new range of realistic scenarios, allowing conclusions to be made based upon a broader evidence base. We simulated randomised controlled trials incorporating prognosis-related treatment switching and investigated the impact of sample size, reduced switching proportions, disease severity, and alternative data-generating models on the performance of adjustment…

Predicting costs over time using Bayesian Markov chain Monte Carlo methods: an application to early inflammatory polyarthritis

Nicola J. Cooper, Paul C. Lambert, Keith R. Abrams +1 more

Statistics and Probability · Health Economics · · cited 52× · DOI ↗ · more like this ·

This article focuses on the modelling and prediction of costs due to disease accrued over time, to inform the planning of future services and budgets. It is well documented that the modelling of cost data is often problematic due to the distribution of such data; for example, strongly right skewed with a significant percentage of zero-cost observations. An additional problem associated with modelling costs over time is that cost observations measured on the same individual at different time points will usually be correlated. In this study we compare the performance of four different multilevel/hierarchical models (which allow for both the within-subject and between-subject variability) for analysing healthcare costs in a cohort of individuals with early inflammatory polyarthritis (IP) who were followed-up annually over a 5-year time period from 1990/1991. The hierarchical models fitted…

Approximate Bayesian inference for random effects meta-analysis

Keith R. Abrams, Bruno Sansó

Statistics and Probability · Statistics in Medicine · · cited 49× · DOI ↗ · more like this ·

Whilst meta-analysis is becoming a more commonplace statistical technique, Bayesian inference in meta-analysis requires complex computational techniques to be routinely applied. We consider simple approximations for the first and second moments of the parameters of a Bayesian random effects model for meta-analysis. These computationally inexpensive methods are based on simple analytical formulae that provide an efficient tool for a qualitative analysis and a quick numerical estimation of posterior quantities. They are shown to lead to sensible approximations in two examples of meta-analyses and to be in broad agreement with the more computationally intensive Gibbs sampling.

Bayesian meta‐analytical methods to incorporate multiple surrogate endpoints in drug development process

Sylwia Bujkiewicz, John R. Thompson, Richard D Riley +1 more

Statistics and Probability · Statistics in Medicine · · cited 44× · DOI ↗ · more like this ·

A number of meta-analytical methods have been proposed that aim to evaluate surrogate endpoints. Bivariate meta-analytical methods can be used to predict the treatment effect for the final outcome from the treatment effect estimate measured on the surrogate endpoint while taking into account the uncertainty around the effect estimate for the surrogate endpoint. In this paper, extensions to multivariate models are developed aiming to include multiple surrogate endpoints with the potential benefit of reducing the uncertainty when making predictions. In this Bayesian multivariate meta-analytic framework, the between-study variability is modelled in a formulation of a product of normal univariate distributions. This formulation is particularly convenient for including multiple surrogate endpoints and flexible for modelling the outcomes which can be surrogate endpoints to the final outcome…

Mixed effects models for healthcare longitudinal data with an informative visiting process: a Monte Carlo simulation study

Alessandro Gasparini, Keith R. Abrams, Jessica K. Barrett +4 more

stat.ME · · cited 38× · arXiv ↗ · more like this ·

Electronic health records are being increasingly used in medical research to answer more relevant and detailed clinical questions; however, they pose new and significant methodological challenges. For instance, observation times are likely correlated with the underlying disease severity: patients with worse conditions utilise health care more and may have worse biomarker values recorded. Traditional methods for analysing longitudinal data assume independence between observation times and disease severity; yet, with healthcare data such assumptions unlikely holds. Through Monte Carlo simulation, we compare different analytical approaches proposed to account for an informative visiting process to assess whether they lead to unbiased results. Furthermore, we formalise a joint model for the observation process and the longitudinal outcome within an extended joint modelling framework. We…

Joint modelling of longitudinal and survival data: incorporating delayed entry and an assessment of model misspecification

Michael J. Crowther, Therése Andersson, Paul C. Lambert +2 more

Statistics and Probability · Statistics in Medicine · · cited 34× · DOI ↗ · more like this ·

A now common goal in medical research is to investigate the inter-relationships between a repeatedly measured biomarker, measured with error, and the time to an event of interest. This form of question can be tackled with a joint longitudinal-survival model, with the most common approach combining a longitudinal mixed effects model with a proportional hazards survival model, where the models are linked through shared random effects. In this article, we look at incorporating delayed entry (left truncation), which has received relatively little attention. The extension to delayed entry requires a second set of numerical integration, beyond that required in a standard joint model. We therefore implement two sets of fully adaptive Gauss-Hermite quadrature with nested Gauss-Kronrod quadrature (to allow time-dependent association structures), conducted simultaneously, to evaluate the…

The inclusion of real world evidence in clinical development planning

on behalf of GetReal Workpackage 1, Reynaldo Martina, David Jenkins +3 more

Statistics and Probability · Trials · · cited 32× · DOI ↗ · more like this ·

BACKGROUND: When designing studies it is common to search the literature to investigate variability estimates to use in sample size calculations. Proprietary data of previously designed trials in a particular indication are also used to obtain estimates of variability. Estimates of treatment effects are typically obtained from randomised controlled clinical trials (RCTs). Based on the observed estimates of treatment effect, variability and the minimum clinical relevant difference to detect, the sample size for a subsequent trial is estimated. However, data from real world evidence (RWE) studies, such as observational studies and other interventional studies in patients in routine clinical practice, are not widely used in a systematic manner when designing studies. In this paper, we propose a framework for inclusion of RWE in planning of a clinical development programme. METHODS: In our…

Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring

Nicholas Latimer, Keith R. Abrams, Uwe Siebert

Statistics and Probability · BMC Medical Research Methodology · · cited 30× · DOI ↗ · more like this ·

BACKGROUND: Treatment switching is common in randomised trials of oncology treatments, with control group patients switching onto the experimental treatment during follow-up. This distorts an intention-to-treat comparison of the treatments under investigation. Two-stage estimation (TSE) can be used to estimate counterfactual survival times for patients who switch treatments - that is, survival times that would have been observed in the absence of switching. However, when switchers do not die during the study, counterfactual censoring times are estimated, inducing informative censoring. Re-censoring is usually applied alongside TSE to resolve this problem, but results in lost longer-term information - a major concern if the objective is to estimate long-term treatment effects, as is usually the case in health technology assessment. Inverse probability of censoring weights (IPCW)…

Bayesian hierarchical meta‐analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data

Tasos Papanikos, John R. Thompson, Keith R. Abrams +4 more

Statistics and Probability · Statistics in Medicine · · cited 27× · DOI ↗ · more like this ·

Surrogate endpoints play an important role in drug development when they can be used to measure treatment effect early compared to the final clinical outcome and to predict clinical benefit or harm. Such endpoints are assessed for their predictive value of clinical benefit by investigating the surrogate relationship between treatment effects on the surrogate and final outcomes using meta-analytic methods. When surrogate relationships vary across treatment classes, such validation may fail due to limited data within each treatment class. In this paper, two alternative Bayesian meta-analytic methods are introduced which allow for borrowing of information from other treatment classes when exploring the surrogacy in a particular class. The first approach extends a standard model for the evaluation of surrogate endpoints to a hierarchical meta-analysis model assuming full exchangeability of…

Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints

Sylwia Bujkiewicz, John R. Thompson, Enti Spata +1 more

Statistics and Probability · Statistical Methods in Medical Research · · cited 27× · DOI ↗ · more like this ·

We investigate the effect of the choice of parameterisation of meta-analytic models and related uncertainty on the validation of surrogate endpoints. Different meta-analytical approaches take into account different levels of uncertainty which may impact on the accuracy of the predictions of treatment effect on the target outcome from the treatment effect on a surrogate endpoint obtained from these models. A range of Bayesian as well as frequentist meta-analytical methods are implemented using illustrative examples in relapsing-remitting multiple sclerosis, where the treatment effect on disability worsening is the primary outcome of interest in healthcare evaluation, while the effect on relapse rate is considered as a potential surrogate to the effect on disability progression, and in gastric cancer, where the disease-free survival has been shown to be a good surrogate endpoint to the…

Mixed-effects models for health care longitudinal data with an informative visiting process: A Monte Carlo simulation study.

Alessandro Gasparini, Keith R. Abrams, Jessica Barrett +4 more

Statistics and Probability · Apollo (University of Cambridge) · · cited 26× · DOI ↗ · more like this ·

Electronic health records are being increasingly used in medical research to answer more relevant and detailed clinical questions; however, they pose new and significant methodological challenges. For instance, observation times are likely correlated with the underlying disease severity: Patients with worse conditions utilise health care more and may have worse biomarker values recorded. Traditional methods for analysing longitudinal data assume independence between observation times and disease severity; yet, with health care data, such assumptions unlikely hold. Through Monte Carlo simulation, we compare different analytical approaches proposed to account for an informative visiting process to assess whether they lead to unbiased results. Furthermore, we formalise a joint model for the observation process and the longitudinal outcome within an extended joint modelling framework. We…

Adjusting for measurement error in baseline prognostic biomarkers included in a time-to-event analysis: a joint modelling approach

Michael J. Crowther, Paul C. Lambert, Keith R. Abrams

Statistics and Probability · BMC Medical Research Methodology · · cited 24× · DOI ↗ · more like this ·

BACKGROUND: Methodological development of joint models of longitudinal and survival data has been rapid in recent years; however, their full potential in applied settings are yet to be fully explored. We describe a novel use of a specific association structure, linking the two component models through the subject specific intercept, and thus extend joint models to account for measurement error in a biomarker, even when only the baseline value of the biomarker is of interest. This is a common occurrence in registry data sources, where often repeated measurements exist but are simply ignored. METHODS: The proposed specification is evaluated through simulation and applied to data from the General Practice Research Database, investigating the association between baseline Systolic Blood Pressure (SBP) and the time-to-stroke in a cohort of obese patients with type 2 diabetes mellitus.…

Impact of model misspecification in shared frailty survival models

Alessandro Gasparini, Mark S. Clements, Keith R. Abrams +1 more

stat.ME · · cited 19× · arXiv ↗ · more like this ·

Survival models incorporating random effects to account for unmeasured heterogeneity are being increasingly used in biostatistical and applied research. Specifically, unmeasured covariates whose lack of inclusion in the model would lead to biased, inefficient results are commonly modelled by including a subject-specific (or cluster-specific) frailty term that follows a given distribution (e.g. Gamma or log-Normal). Despite that, in the context of parametric frailty models little is known about the impact of misspecifying the baseline hazard, the frailty distribution, or both. Therefore, our aim is to quantify the impact of such misspecification in a wide variety of clinically plausible scenarios via Monte Carlo simulation, using open source software readily available to applied researchers. We generate clustered survival data assuming various baseline hazard functions, including mixture…

Assessing causal treatment effect estimation when using large observational datasets

Ellie John, Keith R. Abrams, Christopher E. Brightling +1 more

Statistics and Probability · BMC Medical Research Methodology · · cited 16× · DOI ↗ · more like this ·

BACKGROUND: Recently, there has been a heightened interest in developing and evaluating different methods for analysing observational data. This has been driven by the increased availability of large data resources such as Electronic Health Record (EHR) data alongside known limitations and changing characteristics of randomised controlled trials (RCTs). A wide range of methods are available for analysing observational data. However, various, sometimes strict, and often unverifiable assumptions must be made in order for the resulting effect estimates to have a causal interpretation. In this paper we will compare some common approaches to estimating treatment effects from observational data in order to highlight the importance of considering, and justifying, the relevant assumptions prior to conducting an observational analysis. METHODS: A simulation study was conducted based upon a small…

Joint longitudinal hurdle and time-to-event models: an application related to viral load and duration of the first treatment regimen in patients with HIV initiating therapy

Samuel L. Brilleman, Michael J. Crowther, Margaret May +2 more

Statistics and Probability · Statistics in Medicine · · cited 12× · DOI ↗ · more like this ·

Shared parameter joint models provide a framework under which a longitudinal response and a time to event can be modelled simultaneously. A common assumption in shared parameter joint models has been to assume that the longitudinal response is normally distributed. In this paper, we instead propose a joint model that incorporates a two-part 'hurdle' model for the longitudinal response, motivated in part by longitudinal response data that is subject to a detection limit. The first part of the hurdle model estimates the probability that the longitudinal response is observed above the detection limit, whilst the second part of the hurdle model estimates the mean of the response conditional on having exceeded the detection limit. The time-to-event outcome is modelled using a parametric proportional hazards model, assuming a Weibull baseline hazard. We propose a novel association structure…

Bayesian multi-parameter evidence synthesis to inform decision-making: a case study in metastatic hormone-refractory prostate cancer

Sze Huey Tan (434904), Keith R. Abrams (7579436), Sylwia Bujkiewicz (5629403)

Statistics and Probability · Figshare · · cited 6× · OpenAlex ↗ · more like this ·

In health technology assessment, decisions are based on complex cost-effectiveness\nmodels which require numerous input parameters. When not all relevant estimates are\navailable the model may have to be simplified. Multi-parameter evidence synthesis combines\ndata from diverse sources of evidence which results in obtaining estimates required in\nclinical decision-making that otherwise may not be available. We demonstrate how bivariate\nmeta-analysis can be used to predict an unreported estimate of a treatment effect enabling\nimplementation of a multi-state Markov model, which otherwise needs to be simplified. To\nillustrate this, we used an example of cost-effectiveness analysis for docetaxel in\ncombination with prednisolone in metastatic hormone-refractory prostate cancer. Bivariate\nmeta-analysis was used to model jointly available data on treatment effects on overall\nsurvival and…

Bridging disconnected networks of first and second lines of biologic therapies in rheumatoid arthritis with registry data: Bayesian evidence synthesis with target trial emulation

Sylwia Bujkiewicz, Janharpreet Singh, Lorna Wheaton +4 more

stat.AP · · cited 1× · arXiv ↗ · more like this ·

Objective: We aim to utilise real world data in evidence synthesis to optimise an evidence base for the effectiveness of biologic therapies in rheumatoid arthritis in order to allow for evidence on first-line therapies to inform second-line effectiveness estimates. Study design and setting: We use data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) to supplement RCT evidence obtained from the literature, by emulating target trials of treatment sequences to estimate treatment effects in each line of therapy. Treatment effects estimates from the target trials inform a bivariate network meta-analysis (NMA) of first and second-line treatments. Results: Summary data were obtained from 21 trials of biologic therapies including 2 for second-line treatment and results from six emulated target trials of both treatment lines. Bivariate NMA…

PP254 Double-Counting In Evidence Synthesis Including Routinely Collected Data: Methodological and Practical Considerations

Humaira Hussein, Clareece R. Nevill, Anna Meffen +5 more

Sociology and Political Science · International Journal of Technology Assessment in Health Care · · cited 1× · DOI ↗ · more like this ·

Introduction The use of real-world data, as an alternative to randomized controlled trials, is becoming increasingly common in the evaluation of new health technologies. With this rise in real-world literature, such data will also enter evidence synthesis models. While it can be beneficial to utilize data from all available sources, this can introduce the problem of double-counting of participants. Methods Using a number of case-studies, we discuss and illustrate various issues around double-counting. These include synthesis of studies using the same database or the same subset of participants, overlapping use of intervention arms across studies and the use of registry data from the participants overlapping with those in randomized controlled trials. The implications in research are considered along with common methods used currently to overcome these issues. Results Double-counting of…

The use of registry data to extrapolate overall survival results from randomised controlled trials

Reynaldo Martina, Keith Abrams, Sylwia Bujkiewicz +5 more

stat.AP · · cited 1× · arXiv ↗ · more like this ·

Background: Pre-marketing authorisation estimates of survival are generally restricted to those observed directly in randomised controlled trials (RCTs). However, for regulatory and Health Technology Assessment (HTA) decision-making a longer time horizon is often required than is studied in RCTs. Therefore, extrapolation is required to estimate long-term treatment effect. Registry data can provide evidence to support extrapolation of treatment effects from RCTs, which are considered the main sources of evidence of effect for new drug applications. A number of methods are available to extrapolate survival data, such as Exponential, Weibull, Gompertz, log-logistic or log-normal parametric models. The different methods have varying functional forms and can result in different survival estimates. Methods: The aim of this paper was to use registry data to supplement the relatively short term…

Adjusting for treatment crossover in the METRIC metastatic melanoma (MM) trial for trametinib: Preliminary analysis.

Keith R. Abrams, Nicholas Latimer, Mayur M. Amonkar +3 more

Computational Theory and Mathematics · Journal of Clinical Oncology · · cited 1× · DOI ↗ · more like this ·

9040 Background: In METRIC, a randomized phase III study, trametinib significantly improved PFS (hazard ratio [HR]=0.44 [95% CI 0.31–0.64; p<0.001]) vs chemotherapy (chemo) in patients (pts) with BRAF V600E+ MM and no brain metastases. Median overall survival (OS), a secondary endpoint, has not yet been reached. OS results are likely to underestimate the effect of trametinib as pts progressing on chemo could cross over to experimental treatment (trt). This analysis attempts to adjust for confounding effects of trt crossover on OS in the overall population and first line (1L) subgroup using current METRIC results. Methods: Randomization-based crossover adjustment methods – Rank Preserving Structural Failure Time Models (RPSFTM) and the Iterative Parameter Estimation (IPE) algorithm – were used. We conducted two sets of analyses testing different assumptions regarding the durability of…

Evaluation of methods to adjust for treatment switching in clinical trials

Richard Fox, Lucinda Billingham, Keith R. Abrams

Statistics and Probability · Trials · · cited 1× · DOI ↗ · more like this ·

Treatment switching in clinical trials dilutes estimates of treatment effect which is problematic in decision making, especially in an economic context. In one example 75% of patients crossover from the randomised treatment which emphasises the need to address such bias. We consider methodologies that compensate for this bias.